Patents by Inventor F. Jon Geske

F. Jon Geske has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLUBLE AND MEMBRANE-ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS
    Publication number: 20140377740
    Abstract: Soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins are disclosed, as well as diagnostic and preventative methods using these compositions. Also disclosed are methods including preparation of vaccines, factors (e.g. small molecules) that inhibit LASV infectivity, and diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 25, 2014
    Applicants: BIOFACTURA, INC., THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
    Inventors: Luis M. BRANCO, Alexander MATSCHINER, Megan M. ILLICK, Darryl B. SAMPEY, Robert F. GARRY, Daniel G. BAUSCH, Joseph N. FAIR, Mary C. GUTTIERI, Kathleen A. CASHMAN, Russell B. WILSON, Peter C. KULAKOSKY, F. Jon GESKE
  • Methods and kits for detection of thromboxane A2 metabolites
    Patent number: 8168400
    Abstract: Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: May 1, 2012
    Assignees: Corgenix Medical Corporation, Cayman Chemical Company
    Inventors: F. Jon Geske, Amy Whittier, Daniel Tew, Kirk M. Maxey
  • Methods and kits for detection of thromboxane A2 metabolites
    Patent number: 8105790
    Abstract: Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: January 31, 2012
    Assignees: Corgenix Medical Corporation, Cayman Chemical Company
    Inventors: F. Jon Geske, Amy Whittier, Daniel Tew, Kirk M. Maxey
  • Methods and Kits for Detection of Thromboxane A2 Metabolites
    Publication number: 20110275789
    Abstract: Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
    Type: Application
    Filed: July 21, 2011
    Publication date: November 10, 2011
    Applicants: CAYMAN CHEMICAL COMPANY, CORGENIX MEDICAL CORPORATION
    Inventors: F. Jon Geske, Amy Whittier, Daniel Tew, Kirk M. Maxey
  • SOLUBLE AND MEMBRANE ANCHORED FORMS OF LASSA VIRUS SUBUNIT PROTEINS
    Publication number: 20100261640
    Abstract: The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.
    Type: Application
    Filed: April 10, 2008
    Publication date: October 14, 2010
    Inventors: Luis M. Branco, Alexander Matschiner, Megan M. Illick, Darryl B. Sampey, Robert F. Garry, Daniel G. Bausch, Joseph N. Fair, Mary C. Guttieri, Kathleen A. Cashman, Russell B. Wilson, Peter C. Kulakosky, F. Jon Geske
  • Methods and Kits for Detection of Thromboxane A2 Metabolites
    Publication number: 20100227417
    Abstract: Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
    Type: Application
    Filed: March 30, 2010
    Publication date: September 9, 2010
    Applicants: CORGENIX MEDICAL CORPORATION, CAYMAN CHEMICAL COMPANY
    Inventors: F. Jon Geske, Amy Whittier, Daniel Tew, Kirk M. Maxey
  • Methods and kits for detection of thromboxane A2 metabolites
    Patent number: 7727730
    Abstract: Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: June 1, 2010
    Assignee: Corgenix Medical Corporation
    Inventors: F. Jon Geske, Amy Whittier, Daniel Tew, Kirk M. Maxey